

Stephen P Ackland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/144848/publications.pdf>

Version: 2024-02-01

75
papers

6,930
citations

159525

30
h-index

133188

59
g-index

76
all docs

76
docs citations

76
times ranked

6429
citing authors

#	ARTICLE	IF	CITATIONS
1	Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 791-802.	2.3	17
2	Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. <i>Clinical Colorectal Cancer</i> , 2021, 20, 245-255.	1.0	2
3	Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1603-1617.	0.4	6
4	Science and art of anticancer drug dosing: nine steps to personalised therapy. <i>Internal Medicine Journal</i> , 2020, 50, 992-996.	0.5	0
5	Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies. <i>Hormones and Cancer</i> , 2020, 11, 155-169.	4.9	17
6	Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 357-365.	1.1	3
7	First-in-class human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 151-157.	0.7	2
8	SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. <i>BMC Cancer</i> , 2019, 19, 1229.	1.1	15
9	Quality publishing. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 5-5.	0.7	0
10	Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum. <i>Annals of Surgery</i> , 2017, 265, 882-888.	2.1	77
11	Borderline resectable pancreas adenocarcinoma managed with neoadjuvant chemoradiotherapy: A prospective case series.. <i>Journal of Clinical Oncology</i> , 2017, 35, 499-499.	0.8	0
12	Phase 1 study of infusional or bolus deflexifol (a novel formulation of 5FU, folinic acid, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 To TPS812-TPS812.	0.8	0
13	Deflexifol (a novel formulation of 5FU): Pharmacokinetics in a phase 1 trial in comparison to 5FU.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2530-2530.	0.8	0
14	Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2529-2529.	0.8	0
15	Collaborative Patient-Centered Quality Improvement. <i>Evaluation and the Health Professions</i> , 2016, 39, 475-495.	0.9	5
16	Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. <i>Journal of Neuro-Oncology</i> , 2016, 128, 163-171.	1.4	38
17	Biomedical publishing in 2015 and beyond: challenges and opportunities. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 5-6.	0.7	0
18	The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). <i>European Journal of Cancer</i> , 2016, 55, 15-26.	1.3	45

#	ARTICLE	IF	CITATIONS
19	Oncology patients overwhelmingly support tissue banking. <i>BMC Cancer</i> , 2015, 15, 413.	1.1	15
20	Controversies in the management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 216-227.	0.7	6
21	Mitotane pharmacodynamics in adrenocortical cancer in children and adults.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13532-e13532.	0.8	0
22	Current opinion on optimal treatment for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 597-611.	1.1	30
23	2012: Year in Review “from dragons to snakes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 1-1.	0.7	0
24	Curative Strategies for Liver Metastases from Colorectal Cancer: A Review. <i>Oncologist</i> , 2012, 17, 201-211.	1.9	19
25	Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. <i>Journal of Clinical Oncology</i> , 2012, 30, 3827-3833.	0.8	725
26	2011: Year in Review “from rabbits to dragons. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 1-2.	0.7	0
27	Cancer in Australia: A Model for other Asia-Pacific Countries. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 323-324.	0.7	0
28	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 519-525.	1.1	9
29	Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 963-966.	1.1	10
30	A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2201-2205.	1.2	12
31	Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4498-4504.	0.8	131
32	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3191-3198.	0.8	370
33	Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer. <i>Oncology</i> , 2009, 77, 113-119.	0.9	106
34	Nab-Paclitaxel: a bright new SPARC in taxane therapy of cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 147-150.	0.7	3
35	Molecular Biomarkers in Non-small Cell Lung Cancer “pointing the way to better outcomes from treatment. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 213-214.	0.7	0
36	Norcantharidin Analogues: Synthesis, Anticancer Activity and Protein Phosphatase 1 and 2A Inhibition. <i>ChemMedChem</i> , 2008, 3, 1878-1892.	1.6	64

#	ARTICLE	IF	CITATIONS
37	Cancer registries: Their role in health care delivery in the Asia-Pacific region. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 71-74.	0.7	1
38	Gastrointestinal stromal tumors – A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 185-187.	0.7	0
39	Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study. <i>Medical Journal of Australia</i> , 2007, 186, 292-295.	0.8	35
40	Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele. <i>International Journal of Cancer</i> , 2007, 120, 1930-1934.	2.3	38
41	Reply to the letter to the editor – Classification of thymidylate synthase gene enhancer region polymorphisms. <i>International Journal of Cancer</i> , 2007, 121, 2581-2582.	2.3	0
42	Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6126-6134.	1.4	82
43	Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 7301-7310.	1.4	34
44	Heterocyclic substituted cantharidin and norcantharidin analogues – synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3392-3397.	1.0	90
45	Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 37-43.	0.7	6
46	Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 99-105.	0.7	6
47	Preventing chemotherapy errors: Implementing system changes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 57-58.	0.7	0
48	Thymidylate synthase inhibitors. <i>Update on Cancer Therapeutics</i> , 2006, 1, 403-427.	0.9	16
49	Cervical carcinoma: A common and preventable problem in developing countries. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 69-70.	0.7	1
50	Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2448-2455.	0.8	58
51	A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2005, 93, 1236-1243.	2.9	52
52	Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. <i>Lancet Oncology</i> , The, 2005, 6, 659-668.	5.1	876
53	Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients*. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2004, 31, 677-682.	0.9	14
54	Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 225-232.	1.1	10

#	ARTICLE	IF	CITATIONS
55	Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. <i>Bioorganic Chemistry</i> , 2003, 31, 68-79.	2.0	86
56	Thymidylate synthase inhibitors. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 1-28.	0.5	7
57	Thymidine Phosphorylase in Angiogenesis and Drug Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2002, , 291-294.	0.8	5
58	Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood. <i>Leukemia and Lymphoma</i> , 2002, 43, 2017-2020.	0.6	29
59	Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 223-230.	1.2	48
60	Anticancer Activity and Protein Phosphatase 1 and 2A Inhibition of a New Generation of Cantharidin Analogues. <i>Investigational New Drugs</i> , 2002, 20, 1-11.	1.2	77
61	Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 943-953.	0.8	51
62	Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 2941-2946.	1.0	70
63	Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. <i>Biomedical Applications</i> , 2000, 748, 383-388.	1.7	64
64	Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2000, 343, 905-914.	13.9	2,871
65	Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2355-2355.	0.8	206
66	Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. <i>Drug Resistance Updates</i> , 1999, 2, 205-214.	6.5	45
67	Antifolates in Combination Therapy. , 1999, , 365-382.		3
68	Haemolytic Uraemic Syndrome Associated with Bleomycin, Epirubicin and Cisplatin Chemotherapy: A Case Report and Review of the Literature. <i>Acta Oncologica</i> , 1998, 37, 107-109.	0.8	19
69	Molecular interactions between dynamin and G-protein $\beta\gamma$ -subunits in neuroendocrine cells. <i>Molecular and Cellular Endocrinology</i> , 1997, 132, 61-71.	1.6	20
70	Simultaneous Determination of Dihydrofluorouracil and 5-Fluorouracil in Plasma by High-Performance Liquid Chromatography. <i>Analytical Biochemistry</i> , 1997, 246, 79-85.	1.1	43
71	Leading Article: Oncologic, Endocrine & Metabolic: New antimetabolites in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 1996, 5, 637-679.	1.9	45
72	Combined modality therapy for esophageal carcinoma: Preliminary results from a large Australasian multicenter study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 997-1006.	0.4	53

#	ARTICLE	IF	CITATIONS
73	Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer— toxicity and dose modification: A transtasman radiation oncology group multi-institution study. International Journal of Radiation Oncology Biology Physics, 1995, 31, 305-313.	0.4	26
74	Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clinical Pharmacology and Therapeutics, 1989, 45, 340-347.	2.3	90
75	White Blood Cell Aplasia Associated with Thymoma. American Journal of Clinical Pathology, 1988, 89, 260-263.	0.4	26